Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

8.810 +0.030 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
From Pomerantz LLP
Via GlobeNewswire
3 Unprofitable Stocks in Hot Water
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
Via StockStory
3 Volatile Stocks in Hot Water
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor... 
Via StockStory
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
From NeoGenomics, Inc.
Via Business Wire
A Look at NeoGenomics's Upcoming Earnings Report
 
Via Benzinga
Earnings Scheduled For April 29, 2025
 
Via Benzinga
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via Business Wire
Envista, NeoGenomics, Acadia Healthcare, Astrana Health, and Hims & Hers Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could... 
Via StockStory
Topics Bonds Stocks
NeoGenomics to Participate in Upcoming June Investor Conferences
From NeoGenomics, Inc.
Via Business Wire
Insights Ahead: NeoGenomics's Quarterly Earnings
 
Via Benzinga
3 Healthcare Stocks with Mounting Challenges
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,... 
Via StockStory
Topics Stocks
3 Russell 2000 Stocks in the Doghouse
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
Earnings Scheduled For May 9, 2025
 
Via Benzinga
Assessing NeoGenomics: Insights From 9 Financial Analysts
 
Via Benzinga
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
These three stocks may fly under the radar, but their recent price increases could appeal to investors seeking a momentum play. 
Via MarketBeat
Topics World Trade
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
NeoGenomics Pays Off 1.25% Convertible Senior Notes
From NeoGenomics, Inc.
Via Business Wire
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
 
Via Benzinga
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Tuesday's session: top gainers and losers
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Why NeoGenomics (NEO) Stock Is Nosediving
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below... 
Via StockStory
Topics Artificial Intelligence
Keep an eye on the top gainers and losers in Tuesday's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
 
Via Benzinga
NeoGenomics (NASDAQ:NEO) Misses Q1 Sales Targets, Stock Drops
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the... 
Via StockStory
NeoGenomics Reports First Quarter 2025 Results
From NeoGenomics, Inc.
Via Business Wire
NeoGenomics (NEO) Q1 Earnings Report Preview: What To Look For
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence World Trade
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
From NeoGenomics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.